

Yang Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4419689/publications.pdf>

Version: 2024-02-01

48
papers

2,147
citations

516215

16
h-index

301761

39
g-index

50
all docs

50
docs citations

50
times ranked

4186
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma. <i>International Immunopharmacology</i> , 2022, 108, 108722.	1.7	7
2	Changing causes of death in persons with haematological cancers 1975–2016. <i>Leukemia</i> , 2022, 36, 1850-1860.	3.3	12
3	Inflammation-based Glasgow prognostic score as an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma. <i>Chinese Medical Journal</i> , 2021, 134, 579-581.	0.9	0
4	A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. <i>Leukemia</i> , 2021, 35, 3212-3222.	3.3	15
5	JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. <i>Leukemia</i> , 2021, 35, 2616-2620.	3.3	63
6	Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). <i>Leukemia</i> , 2021, 35, 1661-1670.	3.3	17
7	A predictive score for progression of COVID-19 in hospitalized persons: a cohort study. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 33.	1.1	9
8	NK/T-cell lymphomas. <i>Leukemia</i> , 2021, 35, 2460-2468.	3.3	55
9	Toward the Cure of Acute Lymphoblastic Leukemia in Children in China. <i>JCO Global Oncology</i> , 2021, 7, 1176-1186.	0.8	4
10	Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models. <i>Leukemia</i> , 2021, 35, 3073-3077.	3.3	4
11	Multifunctional DNA mediated spatially confined assembly for antibody orientation: Surpassing sensitivity and accuracy for rituximab detection. <i>Chemical Engineering Journal</i> , 2021, 419, 129613.	6.6	6
12	An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 255-266.	3.2	17
13	DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia. <i>Cancer Communications</i> , 2021, 41, 1116-1136.	3.7	7
14	Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 8831-8839.	0.9	2
15	Stemness Signature Predicts Outcomes and Identifies Candidates for Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1329-1329.	0.6	0
16	Bone Marrow Adipocyte Shapes Metabolism and Immunity in Tumor Microenvironment to Promote Multiple Myeloma. <i>Blood</i> , 2021, 138, 892-892.	0.6	2
17	Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma. <i>Blood</i> , 2021, 138, 459-459.	0.6	2
18	Bone Marrow Adipocyte Promotes Epithelial-Mesenchymal-Transition-like Activation in Multiple Myeloma Via CXCL-12/CXCR4 Axis. <i>Blood</i> , 2021, 138, 1584-1584.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Systematic Construction of an Autophagic Risk Model in Bone Marrow for Prognostic Prediction in Multiple Myeloma. <i>Blood</i> , 2021, 138, 4713-4713.	0.6	0
20	Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant <i>BCR-ABL1 T315I</i> -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP). <i>Blood</i> , 2021, 138, 3598-3598.	0.6	9
21	Effects of Alternative Splicing Events on Acute Myeloid Leukemia. <i>DNA and Cell Biology</i> , 2020, 39, 2040-2051.	0.9	6
22	Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. <i>Leukemia</i> , 2020, 34, 1503-1511.	3.3	208
23	A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection. <i>Annals of Translational Medicine</i> , 2020, 8, 481-481.	0.7	64
24	Systematic Construction and Validation of a Metabolic Risk Model for Prognostic Prediction in Acute Myelogenous Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 540.	1.3	10
25	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. <i>Blood</i> , 2020, 136, 1477-1486.	0.6	43
26	Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6373-6384.	1.6	6
27	Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials. <i>Blood</i> , 2020, 136, 50-51.	0.6	18
28	Prognosis and regulation of an adenylyl cyclase network in acute myeloid leukemia. <i>Aging</i> , 2020, 12, 11864-11877.	1.4	5
29	A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience. <i>Cancer Research and Treatment</i> , 2020, 52, 573-585.	1.3	5
30	An Immune Score Model of the Bone Marrow Micro-Environment Predicts Survival in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2020, 136, 38-38.	0.6	0
31	An Accurate Prognostic Survival Model of Survival Based on Expression of Genes Involved in Plasma Cell Metabolism. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
32	Adipocyte Fatty Acid Binding Protein Promotes Multiple Myeloma through Regulating Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
33	Clinical Investigation and Biological Mechanism of Tigecycline on Coagulation Disorders in Cancer Patients. <i>Blood</i> , 2020, 136, 25-25.	0.6	0
34	An Immune Risk Score Predicts Survival of Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 33-34.	0.6	1
35	Synergistic Antitumor Effect and Mechanism of Chidamide Combined with Gemcitabine, Oxaliplatin or Zanubrutinib in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 14-15.	0.6	28
36	The Role of the HOXA Gene Family in Acute Myeloid Leukemia. <i>Genes</i> , 2019, 10, 621.	1.0	40

#	ARTICLE	IF	CITATIONS
37	Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. <i>International Journal of Hematology</i> , 2019, 110, 458-465.	0.7	2
38	High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. <i>Journal of Cancer</i> , 2019, 10, 3239-3245.	1.2	49
39	SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. <i>Leukemia</i> , 2018, 32, 2659-2671.	3.3	68
40	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. <i>Cancer Cell</i> , 2015, 27, 617-630.	7.7	449
41	Treatment outcome of young children with acute lymphoblastic leukaemia: achievements and directions implied from Shanghai Children's Medical Centre based ALL2005 protocol. <i>British Journal of Haematology</i> , 2015, 169, 267-277.	1.2	8
42	Integrative Genome-Wide Analysis of RNA Binding and Splicing Reveals Complex Loss and Gain of Function Alterations By SRSF2 P95 Mutations in Myelodysplasia. <i>Blood</i> , 2015, 126, 141-141.	0.6	0
43	A Practical Strategy of Monitoring Minimal Residue Disease and Intervention for Central Nervous System Relapse of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 388-393.	0.3	6
44	Targeting of AML1-ETO in t(8;21) Leukemia by Oridonin Generates a Tumor Suppressor-Like Protein. <i>Science Translational Medicine</i> , 2012, 4, 127ra38.	5.8	76
45	Arsenic Trioxide Induces Apoptosis of Burkitt Lymphoma Cell Lines Through Multiple Apoptotic Pathways and Triggers Antiangiogenesis. <i>Oncology Research</i> , 2011, 19, 149-163.	0.6	16
46	C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2450-2455.	3.3	118
47	Dissection of mechanisms of Chinese medicinal formula Realgar- <i>Indigo naturalis</i> as an effective treatment for promyelocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4826-4831.	3.3	688
48	Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1